Establishing delivery route-dependent safety and efficacy of living biodrug mesenchymal stem cells in heart failure patients

doi:10.4330/wjc.v16.i6.339

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (612)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

HTML

311

Figures (1-6)

Tables (1-3)

Sum=432

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=143

Publishing Process of This Article

Item

Count

Browse

Download

Sum=9

Jun 26, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Cardiol. Jun 26, 2024; 16(6): 339-354
Published online Jun 26, 2024. doi: 10.4330/wjc.v16.i6.339

Open in New Tab Full Size Figure Download Figure

Figure 1 PRISMA flow chart. RCT: Randomized controlled trials.

Open in New Tab Full Size Figure Download Figure

Figure 2 Relative risk of death between groups. IC: Intracoronary; IV: Intravenous injection; TEPI: Transepicardial injection; TESI: Transendocardial injection; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 3 Relative risk of serious adverse events between groups. IC: Intracoronary; IV: Intravenous injection; TEPI: Transepicardial injection; TESI: Transendocardial injection; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 4 Changes in left ventricular ejection fraction compared to baseline between groups. IC: Intracoronary; IV: Intravenous injection; TEPI: Transepicardial injection; TESI: Transendocardial injection; WMD: Weighted-mean difference; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 5 Changes in 6-minute walking distance compared to baseline between groups. IC: Intracoronary; IV: Intravenous injection; TEPI: Transepicardial injection; TESI: Transendocardial injection; WMD: Weighted-mean difference; 95%CI: 95% confidence interval.

Open in New Tab Full Size Figure Download Figure

Figure 6 Forest plot of changes in the pro-B-type natriuretic peptide (pg/mL) compared to baseline between groups. IC: Intracoronary; IV: Intravenous injection; TEPI: Transepicardial injection; TESI: Transendocardial injection; WMD: Weighted-mean difference; 95%CI: 95% confidence interval.

Citation: Jihwaprani MC, Sula I, Charbat MA, Haider KH. Establishing delivery route-dependent safety and efficacy of living biodrug mesenchymal stem cells in heart failure patients. World J Cardiol 2024; 16(6): 339-354
URL: https://www.wjgnet.com/1949-8462/full/v16/i6/339.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i6.339